John G. Fort

3.7k total citations · 1 hit paper
65 papers, 2.6k citations indexed

About

John G. Fort is a scholar working on Pharmacology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, John G. Fort has authored 65 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pharmacology, 23 papers in Surgery and 13 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in John G. Fort's work include Inflammatory mediators and NSAID effects (38 papers), Helicobacter pylori-related gastroenterology studies (15 papers) and Antiplatelet Therapy and Cardiovascular Diseases (10 papers). John G. Fort is often cited by papers focused on Inflammatory mediators and NSAID effects (38 papers), Helicobacter pylori-related gastroenterology studies (15 papers) and Antiplatelet Therapy and Cardiovascular Diseases (10 papers). John G. Fort collaborates with scholars based in United States, Sweden and United Kingdom. John G. Fort's co-authors include Jay L. Goldstein, Alfonso E. Bello, Andrew Whelton, Glenn M. Eisen, Steve Zlotnick, Blair S. Lewis, Ian M. Gralnek, William B. White, John L. Abruzzo and Joseph Puma and has published in prestigious journals such as Gastroenterology, Journal of the American College of Cardiology and Annals of Surgery.

In The Last Decade

John G. Fort

64 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo

2005 482 citations Jay L. Goldstein, Glenn M. Eisen et al. Clinical Gastroenterology and Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John G. Fort United States	21	1.4k	1.0k	749	417	392	65	2.6k
Antonio González‐Pérez Spain	27	877 0.6×	678 0.7×	618 0.8×	242 0.6×	109 0.3×	69	2.8k
Peter Finn United States	21	1.5k 1.1×	565 0.6×	1.7k 2.2×	41 0.1×	168 0.4×	33	3.5k
Alberto Gimona United States	12	858 0.6×	705 0.7×	374 0.5×	73 0.2×	558 1.4×	23	2.3k
Mette Charlot Denmark	20	281 0.2×	426 0.4×	986 1.3×	245 0.6×	246 0.6×	39	2.1k
Alessandro Pierucci Italy	22	621 0.4×	229 0.2×	393 0.5×	27 0.1×	167 0.4×	65	1.7k
Anne‐Marie Schjerning Olsen Denmark	22	459 0.3×	387 0.4×	873 1.2×	20 0.0×	145 0.4×	32	1.7k
Giulia Renda Italy	27	610 0.4×	746 0.7×	1.9k 2.5×	11 0.0×	121 0.3×	111	3.5k
Vardaman M. Buckalew United States	32	236 0.2×	269 0.3×	828 1.1×	27 0.1×	77 0.2×	93	3.1k
Allan G. Howatson United Kingdom	14	450 0.3×	393 0.4×	77 0.1×	124 0.3×	52 0.1×	29	1.6k
Joseph L. Blackshear United States	31	195 0.1×	548 0.5×	4.0k 5.3×	60 0.1×	79 0.2×	105	5.0k

Countries citing papers authored by John G. Fort

Since Specialization

Citations

This map shows the geographic impact of John G. Fort's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John G. Fort with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John G. Fort more than expected).

Fields of papers citing papers by John G. Fort

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John G. Fort. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John G. Fort. The network helps show where John G. Fort may publish in the future.

Co-authorship network of co-authors of John G. Fort

This figure shows the co-authorship network connecting the top 25 collaborators of John G. Fort. A scholar is included among the top collaborators of John G. Fort based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John G. Fort. John G. Fort is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldstein, Jay L., David J. Whellan, James M. Scheiman, et al.. (2016). Long‐Term Safety of a Coordinated Delivery Tablet of Enteric‐Coated Aspirin 325 mg and Immediate‐Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk. Cardiovascular Therapeutics. 34(2). 59–66. 7 indexed citations

Holt, Robert J., John G. Fort, Amy Grahn, Jeffrey D. Kent, & Alfonso E. Bello. (2015). Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib. The Physician and Sportsmedicine. 43(3). 200–212. 12 indexed citations

Whellan, David J., Jay L. Goldstein, Byron Cryer, et al.. (2014). PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: Results of two 6-month, phase 3 studies. American Heart Journal. 168(4). 495–502.e4. 26 indexed citations

Cryer, Byron, Mark Sostek, John G. Fort, et al.. (2011). A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: Results from two randomized, parallel-group, placebo-controlled trials. Annals of Medicine. 43(8). 594–605. 21 indexed citations

Gurbel, Paul A., Kevin P. Bliden, John G. Fort, et al.. (2011). Pharmacodynamic Evaluation of Clopidogrel Plus PA32540: The Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) Study. Clinical Pharmacology & Therapeutics. 90(6). 860–866. 6 indexed citations

Fort, John G., et al.. (2011). Pharmacokinetics and Relative Bioavailability of a Fixed‐Dose Combination of Enteric‐Coated Naproxen and Non‐Enteric‐Coated Esomeprazole Magnesium. The Journal of Clinical Pharmacology. 52(5). 670–680. 13 indexed citations

Miner, Philip B., et al.. (2010). Clinical trial: evaluation of gastric acid suppression with three doses of immediate‐release esomeprazole in the fixed‐dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric‐coated esomeprazole 20 mg: a randomized, open‐label, Phase I study in healthy volunteers. Alimentary Pharmacology & Therapeutics. 32(3). 414–424. 18 indexed citations

Fort, John G., et al.. (2010). Analgesic doses of aspirin (ASA) cause significant upper gastrointestinal (UGI) damage: PA65020, a new combination of enteric-coated aspirin (EC-ASA) & immediate-release (IR) omeprazole significantly reduces the incidence of gastroduodenal ulcers (GU/DU). Journal of Pain. 11(4). S41–S41. 1 indexed citations

Miner, Philip B., et al.. (2009). T1972 Pharmacokinetics of Naproxen and Esomeprazole in PN400, a Single-Tablet, Multilayer Formulation of Enteric-Coated Naproxen Coupled with Immediate-Release Esomeprazole. Gastroenterology. 136(5). A–612. 1 indexed citations

10.

Singh, Gurkirpal, John G. Fort, Jay L. Goldstein, et al.. (2006). Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study. The American Journal of Medicine. 119(3). 255–266. 265 indexed citations

11.

Herzog, Thomas J., Robert L. Coleman, K. Gabriel, et al.. (2006). A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. American Journal of Obstetrics and Gynecology. 195(2). 445–453. 50 indexed citations

12.

Goldstein, Jay L., Glenn M. Eisen, Blair S. Lewis, et al.. (2005). Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clinical Gastroenterology and Hepatology. 3(2). 133–141. 482 indexed citations breakdown →

13.

Whelton, Andrew, et al.. (2004). 838-2 Rofecoxib increases cardiovascular events in arthritis patients but celecoxib and nonspecific nonsteroidal anti-inflammatory drugs do not: Results from a large new England health care claims database. Journal of the American College of Cardiology. 43(5). A415–A415. 2 indexed citations

14.

Sowers, James R., William B. White, Bertram Pitt, et al.. (2003). Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure in treated hypertensive patients with osteoarthritis and type 2 diabetes mellitus. Journal of the American College of Cardiology. 41(6). 320–321. 3 indexed citations

15.

Gibofsky, Allan, Gary W. Williams, Frank McKenna, & John G. Fort. (2003). Comparing the efficacy of cyclooxygenase 2–specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo‐controlled trial. Arthritis & Rheumatism. 48(11). 3102–3111. 57 indexed citations

16.

McKenna, Frank, et al.. (2001). COX-2 Specific Inhibitors in the Management of Osteoarthritis of the Knee: A Placebo-Controlled, Randomized, Double-Blind Study. JCR Journal of Clinical Rheumatology. 7(3). 151–159. 42 indexed citations

17.

Whelton, Andrew, et al.. (2001). Cyclooxygenase-2???Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients. American Journal of Therapeutics. 8(2). 85–95. 258 indexed citations

18.

Smith, Karen L. & John G. Fort. (1998). Phalangeal osseous sarcoidosis. Arthritis & Rheumatism. 41(1). 176–179. 9 indexed citations

19.

Cowchock, F. Susan & John G. Fort. (1994). Can Tests for IgA, IgG, Or IgM Antibodies to Cardiolipin or Phosphatidylserine Substitute for Lupus Anticoagulant Assays in Screening for Antiphospholipid Antibodies?. Autoimmunity. 17(2). 119–122. 1 indexed citations

20.

Fort, John G. & John L. Abruzzo. (1988). Reversal of progressive necrotizing vasculitis with intravenous pulse cyclophosphamide and methylprednisolone. Arthritis & Rheumatism. 31(9). 1194–1198. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact